Skip to main content
. 2019 May 24;11(2):157–166. doi: 10.3892/mco.2019.1867

Figure 2.

Figure 2.

Figure 2.

Figure 2.

Figure 2.

OS curves of patients with PDAC. (A) OS of patients with resectable pancreatic head cancer. The difference was not significant (P=0.124). (B) OS rate of node-positive pancreatic head cancer. OS rate of the NAC group was significantly better than that of the Control group in node positive pancreatic head cancer (P=0.016). (C) OS rate of pancreatic body and tail cancer. OS rate was not improved with preoperative chemotherapy in patients with pancreatic body and tail cancer. (D) In pancreatic head cancer patients who received postoperative adjuvant chemotherapy, the OS rate of the NAC group was significantly improved compared with the Control group (P=0.012). PDAC, pancreatic ductal adenocarcinoma; OS, overall survival; NAC, neoadjuvant chemotherapy; MST, median survival time.